Tofacitinib enhances IGF1 via inhibiting STAT6 transcriptionally activated-miR-425-5p to ameliorate inflammation in RA-FLS
- 10 May 2022
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 477 (10) , 2335-2344
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disease, which has been reported closely associated with the dysfunction of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. This study aims to explore the potential therapeutic effect of Tofacitinib, a putative JAK/STAT inhibitor, in RA. Tofacitinib suppressed proliferation and accelerated apoptosis of rheumatoid arthritis synovial fibroblasts (RA-FLS) as confirmed by CCK-8, EdU and Western blot assays. Tofacitinib significantly inhibited expression of pro-inflammatory factors including tumor necrosis factor-α (TNF-α), vascular endothelial growth factor A, matrix metalloproteinase 1, matrix metalloproteinase 3, interleukin-6 and interferon gamma in RA-FLS cells. mechanistically, tofacitinib decreased signal transducer and activator of transcription 6 (STAT6), which transcriptionally activates miR-425-5p, and thus increased insulin like growth factor 1 (IGF1) expression, a target of miR-425-5p in RA-FLS. Overexpression of STAT6 restored the expression of pro-inflammatory factors and proliferation inhibited by Tofacitinib in RA-FLS. Overall, Tofacitinib exerted inhibitory effect on proliferation and inflammation of RA-FLS through modulating STAT6/miR-425-5p/IGF1 signal axis. These findings shed light on the novel strategies for improving RA.Keywords
Funding Information
- The National Natural Science Foundation of China (81801596)
This publication has 37 references indexed in Scilit:
- Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinibEuropean Journal of Pharmacology, 2020
- JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid ArthritisArthritis & Rheumatology, 2018
- The role of the JAK/STAT signal pathway in rheumatoid arthritisTherapeutic Advances in Musculoskeletal Disease, 2018
- Genetic and environmental risk factors for rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2017
- Autoimmunity as a trigger for structural bone damage in rheumatoid arthritisModern Rheumatology, 2017
- The Activity of JAK/STAT and NF-κB in Patients with Rheumatoid ArthritisAdvances in Clinical and Experimental Medicine, 2016
- Methotrexate for treating rheumatoid arthritisCochrane Database of Systematic Reviews, 2014
- Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancyCurrent Opinion in Rheumatology, 2014
- Sensitivity and specificity of 2010 rheumatoid arthritis classification criteriaRheumatology, 2011
- Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritisRheumatology, 2004